SAN ANTONIO, May 5, 2024 /PRNewswire/ -- Johnson & Johnson announced today updated results from an open-label, multicenter, multi-cohort Phase 1 ...
News
- TAR-210 results show 90% recurrence-free survival and 90% complete response in patients ...
- New Real-World Retrospective Analysis Presented at AUA 2024 Reports 86 ... - BioSpace
(Nasdaq: URGN), a biotech company dedicated to ... San Antonio, TX. Among patients with low-grade ... UroGen is a biotech company dedicated to ...
- With indictment, U.S. Rep. Henry Cuellar's deep South Texas ties will again be tested | TPR
Bioscience-Medicine · Border & Immigration ... Bioscience-Medicine · Border & Immigration · Economy & Labor ... San Antonio –– Cuellar has sowed deep ties ...
- Nivolumab With Nab-Paclitaxel Offers a Potential New Option in MIBC - Targeted Oncology
... San Antonio, Texas. 1. For the study, the investigators included patients who were cisplatin ineligible or declined cisplatin-based treatment, had ...
- Moderates win decisive victory for control of North East ISD school board - Texas Public Radio
The high-stakes — and high-dollar — trustee election for the North East Independent School District returned San Antonio's second largest school ...